Please assess the completion status of the following clinical trial:

Trial Title: Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria Stage I/II/IIb: (COMPLETE AND CLOSED TO ACCRUAL)~* Participants must have sickle cell anemia confirmed by hemoglobin analysis~* Participants must report that their pain is at baseline. Additionally, they cannot report an increase in dose or frequency of opioid use in the last 2 weeks prior to drug administration~* Age 21-70 years~* Participants must have the laboratory indices as outlined in the protocol~* Participants must have reliable IV access as determined by the investigator~* Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of the study.~Inclusion Criteria Stage III: (COMPLETE AND CLOSED TO ACCRUAL)~* Participants must have sickle cell anemia confirmed by hemoglobin analysis~* Participant is admitted to the hospital for a pain episode~* Age 21-70 years~* Participants must have the laboratory indices as outlined in the protocol~* Participants must have reliable IV access as determined by the investigator~* Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation~Inclusion Criteria Stage IV: (open, still accruing volunteers)~* Participants must have sickle cell disease confirmed by hemoglobin analysis~* Participant is admitted to the hospital for a pain episode~* Ages of assent (10 to 17 years at DFCI, but different depending on institution)~* Participants must have the laboratory indices as outlined in the protocol~* Participants must have reliable IV access as determined by the investigator~* Participants and parents must have the ability to understand and the willingness to sign a written informed consent and assent document~* Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation~Exclusion Criteria Stage I/II/IIb: (COMPLETE AND CLOSED TO ACCRUAL)~* Participants with a current physician diagnosis of asthma (within last 12 months), require continuous supplemental oxygen, or predicted or current use of some asthma medications.~* Participants with second- or third-degree AV block or sinus node dysfunction~* Have a history of bleeding diathesis~* Have a history of clinically overt stroke~* Have a history of severe hypertension not adequately controlled with anti-hypertensive medications~* Participants who are receiving chronic anti-coagulation or anti-platelet therapy~* Participants with a history of metastatic cancer~* Participants who have had a hospitalization or emergency room visit for any reason in the past 2 weeks~* Participants may not be receiving any other study agents or have received a study agent in the past 30 days~* Uncontrolled intercurrent illness~* Pregnant or breastfeeding women~* Participants with HIV~* Participants who have previously enrolled and received the investigational agent as part of this study~* Participants who are taking medications that may interact with the investigational agent~Exclusion Criteria Stage III: (COMPLETE AND CLOSED TO ACCRUAL)~* Participants with a current physician diagnosis of asthma (within last 12 months), require continuous supplemental oxygen, or predicted or current use of some asthma medications.~* Participants with second- or third-degree AV block or sinus node dysfunction~* Have a history of bleeding diathesis~* Have a history of clinically overt stroke~* Have a history of severe hypertension not adequately controlled with anti-hypertensive medications~* Participants who are receiving chronic anti-coagulation or anti-platelet therapy~* Participants with a history of metastatic cancer~* Participants may not be receiving any other study agents or have received a study agent in the past 30 days~Exclusion Criteria Stage IV: (open, still accruing volunteers)~* Participants with a current physician diagnosis of asthma (within last 12 months), require continuous supplemental oxygen, or predicted or current use of some asthma medications.~* Participants with second- or third-degree AV block or sinus node dysfunction~* Have a history of bleeding diathesis~* Have a history of clinically overt stroke~* Have a history of hypertension not adequately controlled with anti-hypertensive medications~* Participants who are receiving chronic anti-coagulation or anti-platelet therapy~* Participants with a history of metastatic cancer~* Participants may not be receiving any other study agents or have received a study agent in the past 30 days~* Participants with HIV~* Participants who have previously enrolled and received the investigational agent as part of this study~* Participants who are taking medications that may interact with the investigational agent

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Stage 1 (Type: EXPERIMENTAL): 12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
- Stage 2 (Type: EXPERIMENTAL): 24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
- Stage 3 (Type: EXPERIMENTAL): 24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
- Stage 4 (Type: EXPERIMENTAL): 24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
- Stage 2B (Type: EXPERIMENTAL): 48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.

Based on this trial design, predict the completion outcome and termination type (if applicable).